Sign In
Buy CDNA
$38.37
-1.36 (-3.42%)
At Close: Jul 20, 2026
Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNA
03:15am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. raised its holdings in shares of CareDx, Inc. (NASDAQ: CDNA) by 2.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The instituti
CareDx's Growth Prospects With Naveris Keep Me Bullish
08:15am, Monday, 20'th Jul 2026
CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA's AlloHeme gives them longer-term optionali
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
06:20am, Friday, 17'th Jul 2026
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
08:35am, Thursday, 16'th Jul 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
08:30am, Thursday, 16'th Jul 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization o
CareDx Completes Naveris Acquisition and Expands Oncology Reach
12:26pm, Tuesday, 07'th Jul 2026
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder
08:01am, Tuesday, 07'th Jul 2026
CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products div
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
04:05pm, Wednesday, 01'st Jul 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful comp
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
04:05pm, Tuesday, 30'th Jun 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx's CEO Sells 17K Shares
09:38pm, Sunday, 21'st Jun 2026
The CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average of around $24.03 per share on June 15. The transaction represented 2.7% of John Hanna's direct holdi
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
08:41am, Friday, 19'th Jun 2026
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
07:05am, Thursday, 18'th Jun 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Inc (CDNA) Shares Fall 3.4% -- GF Value Says Still Overvalued
08:03pm, Tuesday, 16'th Jun 2026
On June 16, 2026, CareDx Inc (CDNA) shares fell by 3.4% to a current price of $23.22. The stock has experienced a 52-week range with a high of $24.85 and a low
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
04:05pm, Tuesday, 16'th Jun 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
08:04pm, Monday, 08'th Jun 2026
CareDx NASDAQ: CDNA executives outlined the company's strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted d
